2261-PUB: Type 2 Diabetes Mellitus Debut in Peru: The DDPeru Study

Abstract

Objective: To describe the clinical and metabolic characteristics of debut type 2 diabetes mellitus (T2D) Peruvian patients and to evaluate if there are any differences between the different geographical regions. To describe the initial pharmacological treatment of these patients. Methods: Case series study that took place in different regions of Peru, from July 2016 to November 2017. The inclusion criteria were: patient older than 20 years old, ambulatory setting, first time diagnosis of T2D through: fasting glycemia ≥ 126 mg/dl or random glycemia ≥ 200 mg/dl with symptoms, or oral glucose tolerance test (OGTT) ≥ 200 mg/dl on the 2 hour sample. Also, a description of their initial treatment was registered. Results: Five hundred eighty-one patients were identified, from which two hundred eighty-four (48.9%) were women. The average age of diagnosis was 53.2 ± 12.8 years old. Average weight was 77.3 +/- 16.6 kg, from which 228 patients (39.2%) were over weighted and 178 (30.6%) had type I obesity. Average glycemia was 249.4 mg/dl and average HbA1c was 8.9 %. In those who had abdominal ultrasonography (US), 56.7% had fatty liver. Most of the patients that were from Lima or the northern region of the country, had higher levels of glycemia and HbA1c. The T2D patients that were from high altitude presented more often fatty liver in the US, and lower levels of total cholesterol and LDL-c than those patients from the coast. The younger the patient, more cardiometabolic risk factors were present. Sixty percent of the patients received monotherapy, being metformin the preferred drug. Conclusions: Patients with T2D debut from Lima and the northern region of Peru, and also the younger patients, have more cardiometabolic risk factors than their counterparts from the rest of the country and the older ones. We didn’t find any clinical difference between patients from the coast or from high altitude. Metformin was the most prescribed drug to treat these patients. Disclosure J. Rocca: Consultant; Self; Merck KGaA. Other Relationship; Self; Novo Nordisk A/S. M. Calderon: None. A. Whittembury: None. V. Ulloa: Employee; Self; Novo Nordisk A/S. Funding Novo Nordisk Peru S.A.C.